Valuation: Orthocell Limited

Market Cap 153M 103M 93.69M 86.55M 78.12M 147M 9.73B 1.04B 413M 5.2B 388M 379M 16.49B P/E 2027 *
-11.2x
P/E 2028 * -28x
Enterprise Value 124M 84.16M 76.34M 70.52M 63.65M 120M 7.93B 847M 336M 4.24B 316M 309M 13.44B EV / Sales 2027 *
7.79x
EV / Sales 2028 * 4.2x
Free-Float
83.04%
Yield 2027 *
-
Yield 2028 * -
1 day-2.61%
1 week+0.90%
Current month+1.82%
1 month-16.42%
3 months-29.56%
6 months-31.71%
Current year-48.39%
1 week 0.56
Extreme 0.555
0.6
1 month 0.49
Extreme 0.49
0.69
Current year 0.49
Extreme 0.49
1.16
1 year 0.49
Extreme 0.49
1.16
3 years 0.35
Extreme 0.35
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
20/07/26 Buy

Chairman

15,430 0.0057%
17/07/26 Buy 11,573 0.0043%
17/07/26 Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-2.61%+0.90%-49.09%+34.94% 107M
+1.18%-4.47%-15.76%+15.48% 186B
+1.85%-1.89%+7.36%+45.53% 124B
-0.88%-7.59%-15.71%+13.16% 119B
+1.36%-5.00%-43.14%+4.26% 91.43B
+2.96%+5.70%-1.21%+81.72% 66.67B
+1.08%+2.10%+13.49%-7.08% 58.76B
+0.89%+5.00%-1.31%+64.26% 54.99B
-0.68%-0.62%-2.41%+56.27% 49.93B
-1.28%-0.73% - - 35.13B
Average +0.27%-1.42%-11.97%+34.28% 79B
Weighted average by Cap. +0.69%-3.37%-9.75%+29.11%

Financials

2027 *2028 *
Net sales 15.95M 10.8M 9.8M 9.05M 8.17M 15.4M 1.02B 109M 43.15M 544M 40.52M 39.66M 1.72B 30.65M 20.75M 18.83M 17.39M 15.7M 29.59M 1.96B 209M 82.92M 1.05B 77.86M 76.22M 3.31B
Net income -14.4M -9.75M -8.84M -8.17M -7.37M -13.9M -919M -98.18M -38.96M -491M -36.58M -35.81M -1.56B -7.75M -5.25M -4.76M -4.4M -3.97M -7.48M -494M -52.84M -20.97M -264M -19.69M -19.27M -838M
Net Debt -28.25M -19.13M -17.35M -16.03M -14.47M -27.27M -1.8B -193M -76.43M -963M -71.76M -70.25M -3.05B -23.8M -16.11M -14.62M -13.5M -12.19M -22.97M -1.52B -162M -64.39M -812M -60.46M -59.19M -2.57B
Projected Income Statement - Annual - Orthocell Limited
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
13/11/26 A$0.5600 -2.61% 347,019
12/11/26 A$0.5750 -0.86% 214,161
11/11/26 A$0.5800 -2.52% 461,955
10/11/26 A$0.5950 +0.85% 430,387
09/11/26 A$0.5900 +2.61% 456,062
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5600AUD
Average target price
0.9000AUD
Spread / Average Target
+60.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orthocell Limited